Posts tagged TULSA
Profound completes Sonalleve acquisition from Royal Philips

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has completed the acquisition of the Sonalleve MR-HIFU business from Royal Philips (NYSE:PHG; AEX:PHIA).

Read More
Profound Medical to expand collaboration with Royal Philips’, acquire Sonalleve unit

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has agreed to expand an existing collaboration with Royal Philips (NYSE:PHG; AEX:PHIA) and acquire Philips’ Sonalleve MR-HIFU business, establishing Profound as a market leader in magnetic resonance (MR) ultrasound ablation therapy.

Read More
Profound Medical sells first TULSA-PRO in Finland

Profound Medical (OTCQX:PRFMF; TSXV:PRN) has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital, in collaboration with Royal Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.

Read More
Echelon starts Profound Medical at buy

Echelon Wealth Partners initiated coverage of Profound Medical (OTCQX:PRFMF; TSXV:PRN) with a “buy” rating and one-year price target of $4. The stock closed at 78 cents on March 14.

Read More
Profound Medical COO joins XOR-Labs board

Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world's leading center for lung transplantation and a MaRS Innovation company.

Read More
Mackie ups Profound Medical price target to $4.40

Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday.

Analyst Andre Uddin writes that his new valuation is based on applying a multiple of 4.2 times enterprise value to sales on a 2019 sales estimate to $86-million, discounted back by 50%.

Read More